T
Terry Poling
Publications - 4
Citations - 98
Terry Poling is an academic researcher. The author has contributed to research in topics: Internal medicine & Immunogenicity. The author has an hindex of 2, co-authored 2 publications receiving 73 citations.
Papers
More filters
Journal ArticleDOI
Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study
Joanne M. Langley,George Risi,Michael Caldwell,Larry Gilderman,Bruce Berwald,Charles Fogarty,Terry Poling,Dennis Riff,Mira Baron,Louise Frenette,Eric Sheldon,Harry Collins,Marc Shepard,Marc Dionne,Daniel Brune,Linda Ferguson,David W. Vaughn,Ping Li,Louis Fries +18 more
TL;DR: In adults and elderly adults, AS03A-adjuvanted H5N1 candidate vaccine was highly immunogenic for A/Indonesia/05/2005, with cross-reactivity against A/Vietnam/1194/2004.
Journal ArticleDOI
Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
Stefan Andreas,Marco Testa,Laurent Boyer,Guy Brusselle,Wim Janssens,Edward Kerwin,Alberto Papi,Bonavuth Pek,Luis Puente-Maestu,Dinesh Saralaya,Henrik Watz,Tom Wilkinson,Daniela Casula,G. Di Maro,Maria Lattanzi,Luca Moraschini,Sonia Schoonbroodt,Annaelisa Tasciotti,Ashwani Kumar Arora,François Maltais,Jean-Louis Corhay,E. Janssens,Mathias Leys,Murdo Ferguson,Mark Fitzgerald,Irvin Mayers,Shelly A. McNeil,Arnaud Bourdin,Francis Couturaud,L. Dussart,Gabriele Illies,Andreas Eich,Andrea Ludwig-Sengpiel,Francesco Blasi,Stefano Centanni,C. Pomari,J. Echave-Sustaeta,E. Llorca Martínez,Silvia Narejos Pérez,Sergio Pascual-Guardia,Mercè Pérez Vera,M. Terns Riera,William E. Anderson,Gourab Choudhury,A. De-Soyza,Tom M. Wilkinson,Joseph Boscia III,Kenneth Chinsky,Leonard K. Dunn,David F. Erb,Charles Fogarty,H Jackson Downey,Craig Kunz,Terry Poling,Richard Sellman,Barry Sigal,J. D. Southard,Selwyn Spangenthal,Ziad Tannous +58 more
TL;DR: In this article , the authors assessed the efficacy, safety, and immunogenicity of a candidate vaccine containing surface proteins from non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) in patients with COPD.
Journal ArticleDOI
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Ana Strezova,Javier Díez-Domingo,Kamal Al Shawafi,Juan Carlos Tinoco,Meng Shi,P. Pirrotta,A. Mwakingwe-Omari,M. Adams,Anitta Ahonen,Charles P. Andrews,Eugene Athan,Jose-Fernando BarbaGómez,Piero Barbanti,Elisabeth Barberan,Alain Baty,Niklas Bengtsson,J Berger-Roscher,Katarina Berndtsson Blom,Jean Beytout,Loïc Boucher,Céline Boutry,Alain Boye,François Brault,Laurie Breger,Carles Brotons Cuixart,Covadonga Quirós Caso,Christine Cerna,Huey-Shinn Cheng,Hee Jin Cheong,Eun Ju Choo,Clovis Arns da Cunha,Anthony L. Cunningham,Daniel-Ioan Curiac,Benoit Daguzan,Antje Dahmen,Susanta Datta,Maria Giuseppina Desole,Emmanuel Di Paolo,Marc Dionne,Petr Dite,Jan P. Dutz,John Earl,Tamara Eckermann,William Ellison,J. I. Eremenko,Meral Esen,Takashi Eto,Xavier Farrés Fabré,C.E. Farrington,Murdo Ferguson,Pierre Ferrand,Matthew M. Finneran,David Francyk,Marshall Freedman,George Freeman,Antônio Tarcísio Freire,P Gal,Jean-Sébastien Gauthier,Beatrice Gerlach,Wayne Ghesquiere,Iris Gorfinkel,Christine Grigat,Josef Grosskopf,Monika Hamann,Pascal Hanrion,Paul Hartley,Andrew Hastie,Ken Heaton,Agnes Himpel-Boenninghoff,Thomas Horacek,David S.C. Hui,Yieng Huong,Shinn Jang Hwang,Giancarlo Icardi,Gabriele Illies,Junya Irimajiri,Wilson Jacob,Alen Jambrecina,Thiago Junqueira Avelino-Silva,George Kalema,Hyo Youl Kim,Christian Klein,Uwe Dipl.-Ing. Kleinecke,H Koenig,Satu Kokko,Pavel Kosina,Susan Vendetti Koski,Pekka Koskinen,Maximilian Kropp,Rie Kuroki,Outi Laajalahti,Pierre Lachance,Jacob Lee,Jin Soo Lee,Peter Levins,Robert Weisenburger Lipetz,Bo Liu,Chiu-Shong Liu,Martin Lundvall,Luci Magimaiseelan,Mary Beth Manning,Jukka Markkula,Frederick H. Martin,Pyrene Martínez Piera,D. H. McNally,Shelly A. McNeil,Guglielmo Migliorino,B Moeckesch,Stephan Morscher,Michael Mueller,Abul Kashem Mohammad Munir,Christian Melo de Oliveira,Kenjiro Nakamura,Silvia Narejos Pérez,Yuji Naritomi,Patrice Nault,Jose Luiz Neto,Concepción López,Hiroaki Ogata,Åke Olsson,P. Paavola,Dae-Won Park,Janice Patrick,Karlis Pauksens,Mercè Pérez Vera,Lauri I Peltonen,Georg Plaßmann,Airi Poder,Terry Poling,Carol H. Pretswell,Samir Purnell-Mullick,George Raad,Michael Redmond,Philippe Remaud,Ernie Riffer,Patrick H. Robert,Alex Rodríguez Badia,Maria Luisa Rodriguez de la Pinta,Lars Rombo,Robert Rosen,Shari Rozen,Dominique Saillard,Bruno Salaun,Johan Sanmartin Berglund,Joachim Sauter,Axel Schaefer,Isabelle Schenkenberger,Juergen Schmidt,Bernhard Schmitt,K. Schubert,Anne Schuind,Tino F. Schwarz,Ilkka Seppa,Edmund Kwok Yiu Sha,Gerald Shockey,Sylvia Shoffner,Elina Sirnela-Rif,Tommaso Staniscia,Hirohiko Sueki,Shin Suzuki,Denis Taminau,Guy Tellier,Manuel Terns Riera,Azhar Toma,Nicole Toursarkissian,Mark Turner,Benita Ukkonen,Anna Vilella Morató,Juergen Wachter,Brian Robert Webster,Karl R. Wilhelm,Jonathan Wilson,Wilfred W Yeo,Toufik Zahaf,I. Zahharova,Cristiano A. F. Zerbini +175 more
TL;DR: An interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high and the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
Journal ArticleDOI
Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study
TL;DR: A single dose of H3N2c vaccine may be immunogenic and supports further development of MF59-adjuvanted H3n2c vaccines, especially for pediatric populations.